Latest From Theramex
Alvogen has signed marketing deals with local firms in Canada, Israel and South Korea for the teriparatide drug it has licensed from Pfenex. In the US, Pfenex has just completed a human factors study it feels should support a therapeutic equivalence rating for its Forteo rival.
Sanofi returns two partnered assets to Voyager, further unraveling 2015 deal. Celgene drops Mereo cancer candidate ahead of merger with Bristol, while Ultragenyx and Arcturus expand their joint rare disease efforts.
With private equity interest in the health space booming, CVC has taken a controlling stake in Recordati for €3.03bn, at a sharp discount to the Italian company’s share price.
EMA doesn’t suspend, but warns on Ariad’s leukemia drug Iclusig for potential blood clots, while saying combined hormonal contraceptives’ benefit outweighs their risk.
- Generic Drugs
- Therapeutic Areas
- Gynecological, Urological
- Musculoskeletal & Connective Tissue Disorders
- Theramex SPA
- Western Europe
- Parent & Subsidiaries
- Senior Management
Anish Mehta, CEO
Ciarán Barr, CFO
Susanna El-Armale, SVP, Corp. Dev.
Timothy Kneen, EVP, Commercial Operations
Christophe Pelletier, EVP, Mktg. & Communication
- Contact Info
Sloane Square House
1 Holbein Place
London, SW1W 8NS
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.